Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

How I treat multiple myeloma in geriatric patients
Thierry Façon, Xavier Leleu, Salomon Manier
Blood (2023) Vol. 143, Iss. 3, pp. 224-232
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Thierry Façon, Meletios Α. Dimopoulos, Xavier P Leleu, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 17, pp. 1597-1609
Closed Access | Times Cited: 53
Multiple myeloma
Florent Malard, Paola Neri, Nizar J. Bahlis, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 38
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
Xavier Leleu, Cyrille Hulin, Jérôme Lambert, et al.
Nature Medicine (2024) Vol. 30, Iss. 8, pp. 2235-2241
Open Access | Times Cited: 27
Global, Regional, and National Trends in Multiple Myeloma Burden from 1990 to 2021: An Analysis Based on Global Burden of Disease Study 2021
Song Zhou, Jing Zhou, Lianxiang Li, et al.
(2025)
Closed Access
Long-term trends in the burden of multiple myeloma in China: a Joinpoint regression and age-period-cohort analysis based on GBD 2021
Yanyu Zhang, Qing Su, Jiawen Yu, et al.
Frontiers in Public Health (2025) Vol. 13
Open Access
Sustained Improvement in Health‐Related Quality of Life in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient‐Reported Outcomes
Aurore Perrot, Thierry Façon, Torben Plesner, et al.
European Journal Of Haematology (2025)
Open Access
Survival, years of life lost and attrition rates in multiple myeloma patients in France
Aurore Perrot, F. Raguideau, Hélène Denis, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Challenges in Multiple Myeloma Therapy in Older and Frail Patients
Anna Aureli, Beatrice Marziani, Tommaso Sconocchia, et al.
Cancers (2025) Vol. 17, Iss. 6, pp. 944-944
Open Access
Predictive and Prognostic Significance of Patient‐Reported Outcomes for Survival and Adverse Events in Daratumumab‐Treated Multiple Myeloma
Ahmad Y. Abuhelwa, Sara A. Almansour, Ethan Basch, et al.
European Journal Of Haematology (2025)
Open Access
Real‐World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti‐CD38 Antibodies: The EMMY Cohort From 2017 to 2020
Laure Vincent, Olivier Decaux, Aurore Perrot, et al.
Cancer Medicine (2025) Vol. 14, Iss. 6
Open Access
ЛЕЧЕНИЕ ПАЦИЕНТОВ ПОЖИЛОГО И СТАРЧЕСКОГО ВОЗРАСТА С МНОЖЕСТВЕННОЙ МИЕЛОМОЙ МОЖЕТ БЫТЬ УСПЕШНЫМ ПРИ ИСПОЛЬЗОВАНИИ ПЕГИЛИРОВАННОГО ЛИПОСОМАЛЬНОГО ДОКСОРУБИЦИНА, МЕЛФАЛАНА И ПРЕДНИЗОЛОНА
Э.С. Кантакузин, Э.Р. Удабаши, С.С. Сулейманов, et al.
Успехи геронтологии (2025) Vol. 37, Iss. 6, pp. 737-743
Closed Access
New Developments in Myeloma Treatment and Response Assessment
Françoise Kraeber‐Bodéré, Bastien Jamet, Davide Bezzi, et al.
Journal of Nuclear Medicine (2023) Vol. 64, Iss. 9, pp. 1331-1343
Open Access | Times Cited: 9
Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study
Yingjie Zhang, Xinyue Liang, Weiling Xu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 1
Discovery of Momordin Ic that selectively reduces PD-L1 expression in multiple myeloma cells by recruiting SYVN1
Sizhi Wu, Yan Wen, Wei Ma, et al.
Food Bioscience (2024) Vol. 61, pp. 104732-104732
Closed Access | Times Cited: 1
From Triple- to Penta-Exposed Multiple Myeloma: A Real-World Study in a Medicare Population
Thomas E. Delea, Qiufei Ma, Glenn S. Kroog, et al.
Oncology and Therapy (2024) Vol. 12, Iss. 3, pp. 565-583
Open Access | Times Cited: 1
Difficult‐to‐treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results
Marc S. Raab, Elena Zamagni, Salomon Manier, et al.
eJHaem (2023) Vol. 4, Iss. 4, pp. 1117-1131
Open Access | Times Cited: 4
Breaking through Multiple Myeloma: A Paradigm for a Comprehensive Tumor Ecosystem Targeting
Antonio Giovanni Solimando, Markus Krebs, Vanessa Desantis, et al.
Biomedicines (2023) Vol. 11, Iss. 7, pp. 2087-2087
Open Access | Times Cited: 3
Fragile Warriors: Navigating the Delicate Dance of Frailty and CAR-T cell Therapy for Relapsed/Refractory Multiple Myeloma
Reed Friend, Shebli Atrash
Transplantation and Cellular Therapy (2024) Vol. 30, Iss. 3, pp. 253-254
Open Access
Original Paper Optimizing individualized therapy decision-making in multiple myeloma (MM): Integration and impact of the Revised Myeloma Comorbidity Index in the MM-Tumor Board
Esther Dreyling, Gabriele Ihorst, Heike Reinhardt, et al.
Research Square (Research Square) (2024)
Open Access
Real-life experience with first-line treatment with daratumumab, bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation
Amalia Domingo‐González, Rafael Alonso Fernández, Ana Jiménez, et al.
Frontiers in Hematology (2024) Vol. 3
Open Access
Real-life management of patients aged 80 years old and over with multiple myeloma: results of the EMMY cohort
Thomas Chalopin, M. Macro, O. Decaux, et al.
Clinical Lymphoma Myeloma & Leukemia (2024)
Closed Access
The Outcome of Octogenarian Patients with Multiple Myeloma Treated Outside Clinical Studies, Focusing on Tolerability and Efficacy of Treatment
Dana Amsterdam, Ori Grossberger, Natan Melamed, et al.
Cancers (2024) Vol. 16, Iss. 19, pp. 3329-3329
Open Access
Clinical features and treatment of newly diagnosed multiple myeloma with secondary myelofibrosis: a retrospective study
Han Xu, Yu-Jie Xu, Mengying Wang, et al.
Therapeutic Advances in Hematology (2024) Vol. 15
Open Access
ESTRATÉGIAS TERAPÊUTICAS PARA O MIELOMA MÚLTIPLO: UMA ANÁLISE DAS PRÁTICAS ATUAIS
Ryan Rafael Barros De Macedo, José Evandro da Silva Figuerêdo Clayton Rolim Teixeira, Roberto Pimenta da Silva Filho, et al.
LUMEN ET VIRTUS (2024) Vol. 15, Iss. 43, pp. 8355-8362
Open Access
Isatuximab plus pomalidomide and dexamethasone in frail individuals with relapsed/refractory multiple myeloma in Japan
Nami Tagami, Michihiro Uchiyama, Kenshi Suzuki, et al.
International Journal of Hematology (2024)
Open Access
Page 1 - Next Page

Scroll to top